PMCB · PharmaCyte Biotech, Inc.
$0.59
+0.01 (+0.85%)
At close · Jul 28
Market Cap
$6.33M
Shares
10.74M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Joshua N. Silverman | Chairman, Chief Executive Officer and President | $520,257 |
| Carlos A. Trujillo | Officer | $482,017 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Joshua N. Silverman | Chairman, Chief Executive Officer and President | $787,923 |
| Carlos A. Trujillo | Officer | $586,462 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Kenneth L. Waggoner | — | $441,223 |
| Carlos A. Trujillo | Officer | $385,259 |
| Joshua N. Silverman | Chairman, Chief Executive Officer and President | $197,917 |
| Gerald W. Crabtree | — | $66,658 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Kenneth L. Waggoner | — | $919,151 |
| Carlos A. Trujillo | Officer | $631,851 |
| Gerald W. Crabtree | — | $136,749 |
| Joshua N. Silverman | Chairman, Chief Executive Officer and President | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Kenneth L. Waggoner | — | $616,505 |
| Carlos A. Trujillo | Officer | $422,114 |
| Gerald W. Crabtree | — | $137,731 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Michael M. Abecassis | Director | Appointed | 2026-04-02 |
| Wayne R. Walker | Director | Appointed | 2026-04-02 |
| Robert Weinstein | Director | Appointed | 2026-04-02 |
| Jonathan L. Schechter | Director | Appointed | 2026-04-02 |
| Joshua N. Silverman | Director | Appointed | 2026-04-02 |